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Purpose: Vascular adhesion protein (VAP)-1 is an adhesion molecule elucidated as a mediator of the leukocyte recruitment
cascade. The purpose of this study was to investigate the role of VAP-1 in ocular inflammatory neovascularization using
a mouse laser-induced choroidal neovascularization (CNV) model.
Methods: CNV was induced with 532 nm laser irradiation in C57BL/6 mice, and production of VAP-1 protein in the
retinal pigment epithelium (RPE) choroid during CNV formation was examined. CNV animals were treated with the
specific VAP-1 inhibitor U-V002 or vehicle solution, and the volume of CNV tissue was evaluated with volumetric
measurements. Macrophage infiltration into the CNV lesions was evaluated using two different techniques, flatmount
staining and real-time polymerase chain reaction (PCR) for F4/80. The protein levels of intercellular adhesion molecule
(ICAM)-1, monocyte chemoattractant protein (MCP)-1, P-selectin, and vascular endothelial growth factor (VEGF) in the
RPE-choroid were measured with enzyme-linked immunosorbent assay (ELISA).
Results: VAP-1 inhibition significantly suppressed CNV formation in a dose-dependent manner and reduced macrophage
infiltration into CNV lesions. Furthermore, VAP-1 blockade decreased the expression of ICAM-1 and MCP-1, both of
which play a pivotal role in macrophage recruitment.
Conclusions: Our data suggest VAP-1 has an important role during ocular inflammatory neovascularization through
leukocyte recruitment. VAP-1 inhibition may be a novel and potent therapeutic strategy in treating CNV formation.
Vascular adhesion protein (VAP)-1 is a dual function
molecule [1], discovered in synovial endothelial cells [2].
VAP-1 is an adhesion molecule that mediates the leukocyte
recruitment cascade, particularly the extravasation step [1,3],
and is expressed in vascular endothelial cells throughout the
body, such as those in the kidney [4], heart [5], lung [6], and
ocular tissues [7]. In addition, a structural analysis revealed
that VAP-1 has a high sequential homology with a group of
enzymes known as semicarbazide sensitive amine oxidases
(SSAOs) [8]. SSAOs catalyze the formation of inflammation-
related products such as hydrogen peroxide, aldehyde, and
ammonium  [1].  The  accumulating  evidence  indicates  that
VAP-1 is involved in inflammation via leukocyte recruitment
and enzymatic reaction, thereby accounting for the impression
of VAP-1 as dually functional. Recently, VAP-1 has gained
attention as a biomarker and a therapeutic target for systemic
inflammatory diseases [9–11].
We have reported that inhibition of VAP-1 ameliorates
inflammatory changes in rat models of ocular diseases. In the
endotoxin-induced uveitis (EIU) model, we showed that upon
acute inflammation blockade of VAP-1 reduced leukocyte
infiltration in the vitreous cavity and retina [12]. Furthermore,
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we demonstrated that a VAP-1 inhibitor U-V002 decreased
the entrapped retinal leukocytes in the streptozotocin-induced
diabetic  model,  a  chronic  vascular  inflammation  model
induced by hyperglycemia [13]. In addition, using the rat
choroidal  neovascularization  (CNV)  model,  the  VAP-1
inhibitor  suppressed  the  formation  of  CNV,  which  is  a
hallmark of age-related macular degeneration (AMD) and a
representative  type  of  ocular  inflammatory
neovascularization [14].
The objective of this study was to further investigate the
involvement  of  VAP-1  in  ocular  inflammatory
neovascularization using a mouse laser-induced CNV model.
METHODS
Experimental  animals  and  induction  of  choroidal
neovascularization:  Male  C57BL/6  mice  (7–8  weeks  old;
CLEA, Tokyo, Japan) were used. The animals were housed
in plastic cages in a climate-controlled animal facility and
were fed laboratory chow and water ad libitum. All animal
experiments were conducted in accordance with the ARVO
Statement for the Use of Animals in Ophthalmic and Vision
Research and with the protocols approved by the Animal Care
Committee of Keio University School of Medicine.
To  generate  CNV  with  a  laser  injury,  mice  were
anesthetized with 0.2–0.3 ml of 0.5% pentobarbital sodium.
Pupils  were  dilated  with  5.0%  phenylephrine  and  0.8%
tropicamide. CNV was induced with a 532 nm laser (Novus
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593Spectra,  Lumenis,  Tokyo,  Japan).  Five  to  six  laser  spots
(150 mW, 100 µm, 100 msec) were placed in each eye using
a slit-lamp delivery system and a cover glass as a contact lens.
Immunofluorescence microscopy: Seven days after the laser
injury, the animals were perfused with PBS (136.9 mM NaCl,
2.6 mM KCl, 8.1 mM Na2HPO4•12H2O, 1.46 mM KH2PO4,
400  ml/kg  bodyweight),  and  the  eyes  were  enucleated
immediately after perfusion. Frozen sections of the eyes were
prepared. The sections were incubated with 10% normal goat
serum blocking solution (Zymed Laboratories, San Francisco,
CA) and reacted with rat monoclonal antibody against mouse
VAP-1  (1:100;  Abcam,  Cambridge,  MA).  Thereafter,  the
sections were incubated for 2 h at room temperature with
secondary antibodies (1:400, Alexa Fluor 488 goat antirat
immunoglobulin  G  [IgG],  Invitrogen,  Carlsbad,  CA)  and
mounted  with  mounting  media  with  4',6-diamidino-2-
phenylindole  (VECTASHIELD;  Vector  Laboratories,
Burlingame, CA). Photomicrographs were taken with a digital
high-sensitivity  camera  through  an  upright  fluorescent
microscope. As a negative control, the primary antibodies
were  replaced  with  normal-mouse  IgG  (Upstate
Biotechnology, Lake Placid, NY).
Immunoblotting:  After  the  laser  injury,  the  animals  were
sacrificed  with  an  overdose  of  anesthesia,  interperitoneal
injection of 2ml of 5% pentobarbital sodium, at the indicated
time  point.  The  RPE-choroid  tissue  complex  was
microsurgically isolated and placed into 200 µl of lysis buffer
(0.1 v/v % Triton X-100, 10 mM Tris-HCl pH 7.6, 50 mM
NaCl, 29.1 mM Sodium Diphosphate Decahydrate, 47 mM
Sodium Fluoride, 19.4 mM Glycerol 2-phosphate disodium
salthydrate,  1  mM  EDTA,  0.2  mM  EGTA,  pH  7.6.)
supplemented  with  protease  and  phosphatase  inhibitors
(Sigma-Aldrich,  St.  Louis,  MO),  and  then  sonicated.  The
lysate was centrifuged (20,400x g, 15 min, 4 °C), and the
supernatant was collected. Each sample containing an equal
amount of total protein, quantified by NanoDrop (ND-1000;
Thermo, Wilmington, DE), was separated with SDS–PAGE
and  electroblotted  to  polyvinylidene  fluoride  membranes
(Millipore, Billerica, MA). To block the nonspecific binding,
the  membranes  were  washed  with  5%  skim  milk  and
subsequently  incubated  with  monoclonal  antibody  against
mouse VAP-1 (1:250; BD Biosciences) or monoclonal anti-
α-tubulin  antibody  produced  in  mice  (1:1,000;  Sigma-
Aldrich) at 4 °C overnight, followed by incubation with a
Peroxidase-AffiniPure Goat Anti-Mouse antibody (1:1,000;
Jackson ImmunoResearch Laboratories, West Grove, PA).
The signals were visualized with chemiluminescence (ECL
western  blotting  detection  reagents;  GE  Healthcare,
Buckinghamshire,  UK),  according  to  the  manufacturer’s
protocol.
VAP-1  inhibition:  To  block  VAP-1,  we  used  the  specific
VAP-1 inhibitor, U-V002, as described previously [12–14].
U-V002 is a small molecule and a derivative of 1,3-thiazole,
developed and provided by R-Tech Ueno, Ltd., Tokyo, Japan.
Similar to rat SSAO [12], U-V002 has a specific inhibitory
property  against  mouse  SSAO  (half  maximal  inhibitory
concentration  [IC50],  53.1  nM),  while  its  IC50  against  the
functionally related monoamine oxidase A and monoamine
oxidase B is >10 µM. After the laser injury, the inhibitor (0.15
or  0.3  mg/kg  bodyweight/day)  was  administered  to  the
animals by single daily intraperitoneal injections for 7 days.
The control animals received the same regimen of “the vehicle
solution (1 w/v% Polysorbate 80 in Saline, pH 6.0; R-Tech
Ueno, Ltd.).
Choroidal  flatmount:  Seven  days  after  laser  injury  and
treatment  with  the  VAP-1  inhibitor  (0.15  or  0.3  mg/kg
bodyweight/day) or vehicle, the size of the CNV lesions was
quantified  using  the  choroidal  flatmount  technique  [15].
Briefly, mice were sacrificed with an overdose of anesthesia,
and the eyes were immediately enucleated. The eyes were
fixed in 4% PFA in PBS for 5 min. The anterior segment and
retina of each eye were removed to obtain the RPE-choroidal-
scleral  complex,  and  the  complex  was  then  fixed  in  4%
paraformaldehyde for 2 h. The complex was then incubated
with blocking solution (1% BSA, 0.5% Triton X-100, in PBS)
and  reacted  with  fluorescein  isothiocyanate-conjugated
isolectin B4 (1:140; Vector Laboratories, Burlingame, CA).
Thereafter, the complex was mounted with mounting media
(VECTASHIELD;  Vector  Laboratories).  A  scanning  laser
confocal microscope (FV1000; Olympus, Tokyo, Japan) with
the  blue  argon  laser  wavelength  (488  nm)  was  used  to
visualize  CNV.  Horizontal  optical  sections  of  CNV  were
obtained every 1 μm step from the surface to the deepest focal
plane. The CNV-related fluorescence area was measured with
ImageJ (USA National Institutes of Health, Bethesda, MD).
The summation of the whole fluorescent area was used as the
volume of CNV, as described previously [15,16].
Quantification of macrophage infiltration: Three days after
the laser injury and treatment with either the VAP-1 inhibitor
or  vehicle  solution,  the  animals  were  sacrificed  with  an
overdose  of  anesthesia,  and  the  eyes  were  immediately
enucleated. In the same manner as the CNV size measurement,
choroidal flatmounts were prepared and incubated with rat
antimouse F4/80 antigen (1:100; AbD Serotec, Oxford, UK)
and goat polyclonal IgG PECAM-1 antibody (1:100; Santa
Cruz Biotechnology, Paso Robles, CA). Subsequently, the
tissues  were  mounted  with  mounting  media
(VECTASHIELD, Vector Laboratories). Photographs of the
CNV lesions were taken, and the number of F4/80-positive
cells was counted in a masked fashion.
Real-time polymerase chain reaction: The expression levels
of  F4/80,  intercellular  adhesion  molecule  (ICAM)-1  and
monocyte  chemoattractant  protein  (MCP)-1  in  the  RPE-
choroid complex during CNV formation were examined with
real-time polymerase chain reaction (PCR). Briefly, 3 days
after laser treatment the RPE-choroid tissues were obtained
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homogenized  in  extraction  reagent  (TRIzol  Reagent;
Invitrogen).  Total  RNA  was  prepared  according  to  the
manufacturer’s  protocol.  Equal  amounts  of  total  RNA
extracted from the samples were reverse-transcribed with a
High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Foster City, CA) at 37 °C for 1 h in a 15 μl
reaction volume. Subsequently, for quantitative analysis of
expression, a real-time PCR assay was performed (7500Fast;
Applied  Biosystems),  according  to  the  manufacturer’s
protocol.  Primers  and  TaqMan  probes  for  mouse  F4/80,
Icam-1, and Mcp-1 (Pre-Developed TaqMan Assay Reagents)
were purchased from Applied Biosystems, Inc. The cycling
conditions were 50 °C for 2 min, initial denaturation at 95 °C
for 10 min, and 40 cycles at 95 °C for 15 s and 60 °C for 1
min.  The  quantity  of  mRNA  (mRNA)  expression  was
calculated by normalizing the CT (threshold cycle) of F4/80,
ICAM-1, and MCP-1 to the CT of β-actin in the same sample,
according to the comparative ΔΔCT method.
Enzyme-linked immunosorbent assay: Three days after the
laser injury and treatment with either the VAP-1 inhibitor or
vehicle  solution,  the  animals  were  sacrificed  by  cervical
dislocation, and the eyes were immediately enucleated. The
RPE-choroid tissues were carefully scraped from the eyecup
and placed in 200 μl of lysis buffer. The lysate was sonicated
and centrifuged at 20,400x g for 15 min at 4 °C, and the
ICAM-1, MCP-1, P-selectin, and vascular endothelial growth
factor (VEGF) levels in the supernatant were determined with
enzyme-linked immunosorbent assay (ELISA) kits for mouse
ICAM-1,  MCP-1,  P-selectin,  and  VEGF  (R&D  Systems,
Minneapolis, MN) according to the manufacturer’s protocols.
The  total  protein  concentration   (Bradford technique)  was
determined using NanoDrop (ND-1000, Thermo).
Statistical analysis: All results are expressed as mean±SEM
with sample numbers (n) as indicated. The Student t test was
used  for  statistical  comparison  between  the  groups.
Differences between the means were considered statistically
significant when the probability values were <0.05.
RESULTS
VAP-1  expression  in  the  choroid  during  choroidal
neovascularization formation: To determine whether VAP-1
expression alters during CNV formation, we examined the
localization  of  VAP-1  in  CNV  lesions  with
immunofluorescence  staining  and  the  time  course  of  the
VAP-1  protein  levels  with  western  blotting.  VAP-1  was
detected in endothelial cells of CNV and the choroidal vessels
(Figure 1A). However, immunoblotting showed no change in
the protein level of VAP-1 during CNV formation (Figure
1B).
Impact  of  VAP-1  inhibition  during  choroidal
neovascularization formation: To examine whether VAP-1
contributes  to  CNV  formation  in  mice,  we  quantified  the
volume of the CNV in the flatmounts of the RPE-choroid
complex with or without the VAP-1 blockade (Figure 2A).
Seven days after the laser injury, the animals treated with the
VAP-1 inhibitor (0.0015%) showed a significant decrease in
their average CNV size (417189±39836 µm3, n=9), compared
with the vehicle-treated animals (662217±47236 µm3, n=10,
p<0.01; Figure 2B). Furthermore, a higher dose of the VAP-1
inhibitor  (0.003%)  reduced  the  CNV  volume
(222878±19481  µm3,  n=8,  p<0.01)  even  more  than  the
animals  treated  with  the  lower  dose  VAP-1  inhibitor
(0.0015%) (Figure 2B), indicating that the VAP-1 inhibitor
suppresses CNV growth in a dose-dependent manner.
Effect of VAP-1 blockade on macrophage influx: To study
whether VAP-1 inhibition reduces macrophage infiltration
into the CNV lesions, we quantified the number of F4/80-
positive cells in the CNV lesions of animals with and without
VAP-1  inhibitor  treatment  (0.003%).  Macrophages  were
recruited to the CNV lesion at 3 days after the laser injury
(Figure 3A). The number of accumulated macrophages was
significantly reduced by 37.6% in the animals with blockade
of VAP-1 (1.80±0.11 cells/10000 (μm)3, n=4) compared with
those with vehicle treatment (2.88±0.09 cells/10000 (μm)3,
n=3, p<0.01, Figure 3B). Furthermore, real-time PCR showed
that F4/80 mRNA expression was downregulated by 62.1%
in the animals treated with VAP-1 inhibitor (n=9) compared
to that of the vehicle-treated animals (n=10, Figure 3C), in
accord with the counted data of the infiltrating macrophages
in the CNV lesions.
Suppression  of  adhesion  molecules  and  inflammatory
molecules  by  VAP-1  blockade:  To  further  explore  the
mechanisms by which the VAP-1 blockade suppresses CNV
formation,  we  measured  the  levels  of  the  inflammation-
associated  molecules,  ICAM-1,  MCP-1,  P-selectin,  and
VEGF in the RPE-choroid complex with or without VAP-1
inhibition  (0.003%)  at  3  days  after  laser  treatment.  The
ICAM-1  (38.59±3.26  ng/mg,  n=10)  and  MCP-1
(undetectable,  n=10)  protein  levels  in  the  RPE-choroidal
complexes  of  mice  treated  with  vehicle  solution  were
significantly increased (ICAM-1, 134.05±9.28 pg/mg, n=10,
p<0.05, Figure 4A; MCP-1, 28.41±3.97 pg/mg, n=9, p<0.05,
Figure  4B)  at  3  days  after  laser  injury.  The  ICAM-1
(81.47±4.67 pg/mg) and MCP-1 (14.19±3.50 ng/mg) protein
levels  were  significantly  reduced  in  the  RPE-choroidal
complexes  of  the  laser-treated  animals  that  received  the
inhibitor compared with the vehicle controls (Figure 4A,B).
In accord with our ELISA data, real-time PCR showed that
the  mRNA  expression  levels  of  Icam-1  and  Mcp-1  were
downregulated  by  33.4%  and  11.1%,  respectively,  in  the
animals treated with VAP-1 inhibitor (n=9) compared to that
of the vehicle-treated animals (n=10).
Similarly, the P-selectin (0.16±0.04 ng/mg, n=10) and
VEGF (18.64±1.13 pg/mg, n=10) protein levels in the RPE-
choroid complexes of normal mice were significantly lower
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mg, n=10, p<0.05, Figure 4C; VEGF, 31.25±3.94 pg/mg,
n=10,  p<0.05,  Figure  4D,  respectively).  However,  the  P-
selectin (0.91±0.08 pg/mg) and VEGF (24.97±1.80 pg/mg)
protein levels were not significantly reduced in the RPE-
choroid complex of the animals treated with VAP-1 inhibitor
(Figure 4C,D).
DISCUSSION
In  the  present  study,  VAP-1  inhibition  suppressed  the
expression of MCP-1 and ICAM-1, both of which play a
pivotal role in macrophage recruitment [17,18]. In addition,
VAP-1  blockade  decreased  the  number  of  infiltrated
macrophages into the CNV lesions, which resulted in the
suppression of CNV formation. Our data indicate the potential
of VAP-1 as a therapeutic target in the treatment of CNV.
In accord with a previous study [14], the VAP-1 protein
was detected in the CNV and choroid vessels. Since our and
other  groups  have  demonstrated  that  leukocyte  adhesion
molecules such as ICAM-1 and E-selectin were upregulated
in the RPE-choroid complex with the laser-induced CNV
model [14,17–19], this led us to the idea that VAP-1 was also
upregulated in the CNV lesion and/or choroid during CNV
formation. However, our immunoblotting study revealed that
VAP-1 expression was, unexpectedly, unchanged in the RPE-
choroid complex including the CNV lesions. The current data
indicate  that,  unlike  these  other  leukocyte  adhesion
molecules, VAP-1 likely is not modified in the choroid during
CNV  formation.  Notably,  VAP-1  was  not  increased  by
cytokine  stimulation  in  cultured  hepatic  endothelial  cells
[20], and yet VAP-1 is markedly relevant to various liver
diseases. The current data indicate that VAP-1 is a unique
molecule  that  contributes  to  CNV  formation  without
augmentation.
VAP-1 inhibition showed antiangiogenic effects on CNV
growth  in  a  dose-dependent  manner.  Thus  far,  extensive
efforts have been focused on the therapeutic property of the
VAP-1 inhibitor in systemic diseases such as stroke [21],
uveitis [12], and lung injury [22], all of which arise from the
inflammatory response. Similarly, inflammation underlies the
pathogenesis in CNV formation [23]. Therefore, it is plausible
that VAP-1 inhibition attenuates CNV formation, which is
caused by chronic inflammation in human AMD. Our study
elucidated that the mechanism to suppress CNV formation by
VAP-1 inhibition is, at least in part, due to the reduction of
macrophage infiltration into the CNV lesion. We previously
demonstrated  the  decreased  number  of  macrophages
surrounding the CNV lesions after VAP-1 blockade using
Figure 1. Localization and expression of VAP-1 in the choroid and CNV. A and B: Representative micrographs of a laser-induced CNV lesion.
(A) Phase contrast image. (B) Fluorescent micrograph of VAP-1 (red) and cell nuclei (blue). Arrowheads and arrows indicate the localization
of VAP-1 in the CNV and choroidal vessels, respectively. C: Immunoblotting analysis of VAP-1 and α-tubulin expression in the RPE-choroidal
complex after laser injury.
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596immunofluorescence  staining  [14],  and  the  current  data,
generated  by  different  experimental  techniques  able  to
specifically identify macrophages, i.e., flatmount staining and
real-time  PCR  for  F4/80,  supported  the  previous  finding.
Additionally, real-time PCR and ELISA data showed that
VAP-1 blockade decreased MCP-1 expression in the RPE-
choroid complex during CNV formation. In accord with our
data,  researchers  recently  reported  that  VAP-1  regulates
monocyte recruitment to the tissues [24,25]. Furthermore,
VAP-1 is involved in angiogenesis and tumor growth via
controlling  the  migration  of  Gr-1+CD11b+  myeloid  cells,
which comprise immature macrophages and dendritic cells
playing  a  pivotal  role  in  tumor  angiogenesis  [26].  Taken
together, the accumulating evidence indicates the importance
of VAP-1 for angiogenesis.
The current data showed VAP-1 blockade caused the
reduction of ICAM-1 in the RPE-choroid complex, whereas
the data showed only a trend toward reduced P-selectin levels
in  the  choroid  with  CNV.  Using  an  animal  model  that
manifests acute and severe ocular inflammation, the rat EIU
model, we previously demonstrated that VAP-1 inhibition
downregulated the expression of ICAM-1 and P-selectin in
the inflamed retina [12]. In the previous study, we speculated
from the data that the downregulation of ICAM-1 and P-
selectin expression was due to reduced hydrogen peroxide
generation  through  the  enzymatic  activity  of  VAP-1,  the
regulator for expression of the adhesion molecules [27,28].
Our data indicate that VAP-1 blockade reduces macrophage
recruitment into the CNV lesion indirectly via suppression of
Figure 2. Impact of VAP-1 blockade on
CNV  formation.  A  and  B:
Representative  micrographs  of  CNV
lesions in the choroidal flatmounts from
an animal treated with vehicle or VAP-1
inhibitor.  Red  dashed  line  shows  the
extent of the CNV lesions stained with
FITC-conjugated  isolectin  B4  in
flatmounted choroids. C: Quantitative
analysis of CNV size. Bars show the
average CNV size in each group. Values
are mean±SEM (n=9 to 10). *, p<0.05
**, p<0.01.
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597other  adhesion  molecules,  in  addition  to  the  blockade  of
VAP-1 per se.
Thus far, previous studies have demonstrated that marked
suppression  of  VEGF  is  crucial  for  attenuation  of  CNV
formation in the laser-induced CNV model [15,17]. However,
in this study VAP-1 blockade showed weak inhibitory effects
on VEGF, a key molecule for angiogenesis, whereas CNV
formation  was  significantly  suppressed.  Since  the  data
showed a trend toward reduced VEGF levels in the choroid
with CNV, VAP-1 inhibition may have a weak suppressive
effect on VEGF expression. Alternatively, these data may
indicate  that  VAP-1  inhibition  ameliorates  ocular
Figure 3. Impact of VAP-1 blockade on
macrophage infiltration in CNV. A–F:
Representative  micrographs  of  F4/80
immunostaining in CNV lesions from
an animal treated with vehicle or VAP-1
inhibitor. (Left) CNV lesions stained for
PECAM-1.  (Middle)
Immunofluorescence  staining  for
F4/80.  (Right)  Merged  image.  G:
Quantitative analysis of F4/80-positive
cells  in  CNV  lesion.  Bars  show  the
average  of  the  number  of  infiltrated
macrophages in each group. Values are
mean±SEM (n=3 to 4). *, p<0.05. H:
Quantitative real-time PCR analysis of
F4/80 expression in animals treated with
vehicle or VAP-1 inhibitor (n=9 to 10).
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598angiogenesis  through  mechanism(s)  other  than  VEGF
expression.  Further  evaluation  is  needed  to  elucidate  the
detailed mechanism(s).
In  conclusion,  the  current  data  support  our  previous
findings  that  VAP-1  plays  a  pivotal  role  in  macrophage
infiltration into the CNV lesions in the laser-induced CNV
model, whereas the protein level of VAP-1 is sustained in RPE
and  choroidal  tissue  during  CNV  formation,  indicating  a
unique property of VAP-1 that promotes angiogenesis without
molecular upregulation. Furthermore, previous and current
data show that the role of VAP-1 in CNV formation is not
limited to a single animal species, but appears to be a general
phenomenon  of  rodent  biology  and  possibly  mammalian
biology. Whereas optimization and safety evaluation of the
inhibitor  compound  are  still  required,  this  study  raised
expectations for the possibility of VAP-1 inhibitor as a novel
and  potent  therapeutic  strategy  in  the  treatment  of  CNV
formation.
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